GSK

News
GSK taps Hansoh for another cancer ADC candidate

GSK taps Hansoh for another cancer ADC candidate

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront